Q1/25 Financials of Cancer Drug Developer Released
Source: Dr. Douglas Loe  (6/12/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report. More >

Biotech Firm Unveils Diabetes Breakthrough in Canada
Source: Streetwise Reports  (6/10/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes. More >

New RA Drug Shown to Work, Be Safe
Source: Dr. Martin Fan  (6/10/25)
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report. More >

Analyst Likes Co. Developing Immuno-oncology Drugs
Source: Dr. Matthew Keller  (6/10/25)
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report. More >

Co.'s New Cancer Drug Shows Promise
Source: Jason Kolbert  (6/9/25)
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report. More >

Biotech Co. Reaches MS Clinical Program Milestones
Source: Jason Kolbert  (6/9/25)
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report. More >

Phase 2b Trial Data on Treatment for Inflammation Due Soon
Source: Dr. Jonathan Aschoff  (6/9/25)
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report. More >

Canadian Biotech Advances High-Impact DDR Programs
Source: Streetwise Reports  (6/6/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy. More >

Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports  (6/6/25)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock. More >

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports  (6/6/25)
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

More >

Data Readout Positive from Trial of New Schizophrenia Drug
Source: Jason Kolbert  (6/4/25)
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report. More >

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada
Source: Streetwise Reports  (5/30/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market More >

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern
Source: Clive Maund  (5/27/25)
Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy. More >

Co. Poised to Begin Major New Bull Market
Source: Clive Maund  (5/23/25)
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy. More >

Treatment.com AI's Rocket Doctor Expands US Reach and Drives New Growth Through Virtual ER Innovation
Source: Streetwise Reports  (5/23/25)
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) virtual care subsidiary, Rocket Doctor, has expanded its core virtual care services into New York and California. Separately, its virtual ER program, designed to reduce unnecessary emergency room visits, continues to demonstrate a strong impact. Over a 12-month period between 2023 and 2024, Rocket Doctor reported an 88% year-over-year increase in revenue." More >

Centrally Positioned AI Co. Platform Designed To Transform Healthcare
Source: Clive Maund  (5/21/25)
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA). More >

Co. Prepares to Roll Out Wound Irrigating Solution
Source: Richard Ryan  (5/21/25)
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report. More >

Interim Data From TID Trial Are Positive
Source: Streetwise Reports  (5/15/25)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. More >

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Source: Streetwise Reports  (5/13/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential. More >

Biopharma Receives PDUFA Date for Lead Program
Source: Jason Kolbert  (5/9/25)
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report. More >

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell  (5/1/25)
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report. More >

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado  (5/1/25)
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Source: Streetwise Reports  (4/29/25)
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock. More >

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports  (4/28/25)
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.

More >